Clinical Trials

Have you been diagnosed with orthostatic intolerance? This study aims to find out how the body’s regulation of basic functions, such as heart rate and blood pressure, is altered in people who have orthostatic intolerance. This condition, which has an unknown cause, is characterized by a racing heartbeat, dizziness, lightheadedness, and other symptoms that occur when a person stands up. To participate in this study, you must be between 18 and 80 years old and have orthostatic intolerance. This study is located in Nashville, Tennessee.

Did you develop atrial fibrillation after coronary artery bypass graft (CABG) surgery? Did you develop atrial fibrillation after a coronary artery bypass grafting (CABG) surgery? This study is looking at how well oral anticoagulation medicines work to prevent complications, such as blood clots and heart attack, for patients who experience post-operative atrial fibrillation (POAF). This study is in multiple locations around the country.

Are you a female between 18 and 55 years old who has postural tachycardia syndrome (POTS)? This study is looking at the sympathetic nervous system and its effect on the increased heart rate and dizziness upon standing that people with POTS experience. This study is located in Nashville, Tennessee.

Does your child have asthma that is not well controlled? This study will evaluate different ways to treat asthma for children is certain communities. Your child may be able to participate if they are between 5 and 12 and if you live in certain areas of Colorado where the study is taking place.

Do you have asthma and obesity and live near Aurora, Colorado? Obesity can lead to widespread inflammation that may make asthma worse. This study will test whether a medicine called CXA-10 reduces inflammation in the airways and body and improves asthma symptoms in people who have obesity. To participate in this study, you must be between 18 and 65 years old, have a BMI of 30 or greater, and have been on long-acting controller medicine—such as inhaled corticosteroids or long-acting beta2-agonists—for at least three months. This study is located in Aurora, Colorado.